摘要
肿瘤免疫逃逸在血液系统恶性肿瘤的发生发展中起重要作用,免疫治疗成为当前研究的热点。CD47分子是一种广泛表达于正常细胞及肿瘤细胞表面的高度糖基化跨膜蛋白,其与信号调节蛋白α(SIRPα)、血小板反应蛋白1(TSP-1)、整合素相结合,在炎症与肿瘤免疫方面发挥重要作用。CD47与巨噬细胞表面的SIRPα结合,抑制巨噬细胞的吞噬作用,产生免疫逃逸,从而促进血液系统恶性肿瘤的发生与发展。过表达CD47在多种血液肿瘤中已被证实与预后不良相关。以CD47为治疗靶点的多个药物正在多个类型的血液肿瘤中进行临床前和临床研究,部分药物显示出良好的安全性和极具前景的疗效。本文就CD47的结构与功能、CD47与肿瘤相关巨噬细胞(TAM)、CD47在血液系统恶性肿瘤免疫逃逸中的作用以及CD47靶向药物的研究进展进行综述。
Tumor immune escape plays a key role in the occurrence and development of hematological malignancies.At present,immunotherapy has become a research focus.CD47 is a highly glycosylated transmembrane protein widely ex-pressed on the surfaces of normal cells and tumor cells.Combined with the signal regulatory proteinα(SIRPα),thrombos-pondin 1(TSP-1)and integrin,CD47 plays an important role in inflammation and tumor immune escape.CD47 on the sur-faces of tumor cells binds to the SIRPαon the surfaces of macrophages,inhibiting the phagocytosis of macrophages and pro-ducing tumor immune escape,thus promoting the occurrence and development of hematological malignancies.It has been proven in a variety of hematological malignancies that overexpression of CD47 is associated with poor prognosis.Many drugs targeting CD47 are undergoing preclinical and clinical studies in many types of hematological malignancies,and some of the drugs have shown good safety and promising efficacy.This paper summarizes the structure and function of CD47,the relation between CD47 and tumor-associated macrophage(TAM),the role of CD47 in immune escape of hemato-logical malignancies,and the research progress of CD47-targeted drugs.
作者
覃利平
肖玲
曾若兰
贺怡子
李亚军
周辉
QIN Liping;XIAO Ling;ZENG Ruolan;HE Yizi;LI Yajun;ZHOU Hui(Graduate Collaborative Training Base of Hunan Cancer Hospital,Hengyang Medical School,University of South China,Hengyang,421001,Hunan,China;School of Basic Medical Science,Central South University,Changsha,410013,Hunan,China;Department of Lymphoma&Hematology,Hunan Cancer Hospital,Changsha,410013,Hunan,China)
出处
《肿瘤药学》
CAS
2023年第5期550-558,共9页
Anti-Tumor Pharmacy
基金
湖南省自然科学基金(2021JJ30425)
长沙市自然科学基金(kq2014206)
湖南省卫生健康委科研计划项目(20201659)
湖南省肿瘤医院“科研攀登计划”(ZX2020003)。
